When was Crescita Therapeutics founded?

Crescita Therapeutics was founded in 2016 and raised its 1st funding round 1 year after it was founded.

Where is Crescita Therapeutics located?

Crescita Therapeutics is headquartered in Mississauga, Canada.

Who is the current CEO of Crescita Therapeutics?

Daniel Chicoine and Serge Verreaul s of Crescita Therapeutics.

How many employees does Crescita Therapeutics have?

As of Aug 31, 2026, the latest employee count at Crescita Therapeutics is 61.

Is Crescita Therapeutics a funded company?

Crescita Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Post IPO round on Aug 29, 2017.

When was the latest funding round of Crescita Therapeutics?

Crescita Therapeutics' latest funding was a $***** Post IPO round on Aug 29, 2017, with participation from 1 investor.

Where does Crescita Therapeutics rank among its competitors?

Crescita Therapeutics ranks 233rd amongst 2145 active competitors, of which 487 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was LifeMine Therapeutics, which secured $75M in Aug, 2026.

Who are the top competitors of Crescita Therapeutics?

Crescita Therapeutics' top competitors include Revance Therapeutics, Antheia and Transcenta. Among them, LifeMine Therapeutics secured the most recent funding round in August, 2026.

Crescita Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Crescita Therapeutics is an acquired company based in Mississauga (Canada), founded in 2016. It operates as a Developer of over-the-counter and prescription products for the treatment and care of skin diseases. Crescita Therapeutics has raised an undisclosed amount in funding. The company has 2145 active competitors, including 487 funded and 374 that have exited. Its top competitors include companies like Revance Therapeutics, Antheia and Transcenta.

Company Details

Developer of over-the-counter and prescription products for the treatment and care of skin diseases. It offers Pliaglis, a topical local anaesthetic cream; pro-derm hero products, premiology. Its drug pipeline includes Mical for the treatment of Psoriasis and Mical for Dermatological skin treatment. The company is using its proprietary drug delivery technology (Multiplexed molecular penetration enhancers (MMPE™) and DuraPeel™) to develop formulations.

Key Metrics

Founded Year

2016

Location

Mississauga, Canada

Stage

Acquired

Latest Funding Round

Post IPO, Aug 29, 2017, $*****

Investors

Bloom Burton

Ranked

233^rd among 2145 active competitors

Employee Count

61 as on Aug 31, 2026

Investment & Acquisitions

The Best You & 1 more

Similar Companies

Revance Therapeutics & 2900 more

Exit Details

Acquired

View Crescita Therapeutics' full profile

Crescita Therapeutics got acquired on Mar 16, 2026.

Click here to take a look at Crescita Therapeutics's acquisition in detail

Crescita Therapeutics has raised funding over 1 round. Its latest funding round was a Post IPO round on Aug 29, 2017 for $*****. 1 investor participated in its latest round. Crescita Therapeutics has 1 institutional investor.

Here is the list of recent funding rounds of Crescita Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 29, 2017	9523078	Post IPO	9646342	7731728	2125836	6393370

Access funding benchmarks and valuations. Sign up today!

View details of Crescita Therapeutics's funding rounds and investors

Crescita Therapeutics' employee count trend

Crescita Therapeutics has 61 employees as of Aug 26. Here is Crescita Therapeutics's employee count trend over the years:

Employee count trend for Crescita Therapeutics

Uncover Crescita Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Crescita Therapeutics include Revance Therapeutics, Antheia and Transcenta. Here is the list of Top 10 competitors of Crescita Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Revance Therapeutics 2002, Newark (United States), Acquired	Developer of neurotoxin aesthetic and therapeutic products for skin treatments	$155M	EW Healthcare Partners, Delphi Ventures & 16 others	70/100
2nd	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
3rd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
4th	Lineage Cell Therapeutics 1990, Carlsbad (United States), Public	Developer of cell based therapies for the treatment of cancer, eye disease and spinal disorders	$45.8M	State of California, Juvenescence & 4 others	65/100
5th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Loayal Valley Capital, Sino Biopharmaceutical ... & 18 others	65/100
6th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 14 others	64/100
7th	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	SDIC Innovation, CMB International Capital ... & 4 others	64/100
8th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
9th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	TA Associates, UBS & 1 others	63/100
10th	LifeMine Therapeutics 2016, Watertown (United States), Series E	Developer of novel drugs from fungi via genome mining and recombinant overexpression	$563M	Fidelity Investments, 6 Dimensions Capital ... & 17 others	62/100
233rd	Crescita Therapeutics 2016, Mississauga (Canada), Acquired	Developer of over-the-counter and prescription products for the treatment and care of skin diseases	-	Bloom Burton	43/100